News coverage about Dexcom (NASDAQ:DXCM) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dexcom earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 47.3872334179396 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
Several equities analysts have recently issued reports on DXCM shares. BidaskClub lowered Dexcom from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. Zacks Investment Research raised Dexcom from a “sell” rating to a “hold” rating in a research note on Friday, March 16th. Northcoast Research reaffirmed a “buy” rating on shares of Dexcom in a research note on Sunday, March 4th. Piper Jaffray set a $78.00 price target on Dexcom and gave the company a “buy” rating in a research note on Friday, March 23rd. Finally, ValuEngine lowered Dexcom from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Dexcom presently has an average rating of “Buy” and a consensus price target of $67.38.
NASDAQ DXCM traded down $0.27 on Friday, reaching $72.47. The company had a trading volume of 663,099 shares, compared to its average volume of 1,257,262. The company has a market capitalization of $6,394.29, a PE ratio of -124.95 and a beta of -0.01. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78. Dexcom has a 52 week low of $42.62 and a 52 week high of $81.91.
Dexcom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. The business had revenue of $221.00 million during the quarter, compared to the consensus estimate of $217.82 million. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%. sell-side analysts predict that Dexcom will post -0.56 earnings per share for the current fiscal year.
In other Dexcom news, Chairman Terrance H. Gregg sold 10,000 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $55.91, for a total value of $559,100.00. Following the completion of the sale, the chairman now directly owns 484,559 shares in the company, valued at $27,091,693.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard Doubleday sold 2,581 shares of the stock in a transaction dated Friday, March 23rd. The stock was sold at an average price of $68.44, for a total value of $176,643.64. Following the completion of the sale, the executive vice president now owns 94,429 shares of the company’s stock, valued at $6,462,720.76. The disclosure for this sale can be found here. Insiders sold 35,854 shares of company stock valued at $2,302,881 in the last quarter. 1.70% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Dexcom (DXCM) Getting Somewhat Favorable Media Coverage, Accern Reports” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/21/dexcom-dxcm-getting-somewhat-favorable-media-coverage-accern-reports.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.